Novo Nordisk Stock Falls 6% Despite Raised Guidance - Why Wegovy's US Slowdown Still Spooked Investors

What Happened

Danish pharmaceutical giant Novo Nordisk (NVO) reported second-quarter results and raised its full-year sales guidance, narrowing its expected range from a decline of 4% to 12% to a decline of 0% to 6%. Normally, a guidance raise is read as good news. This time it wasn't: shares still fell more than 6%.

The problem was buried in the details. Injectable Wegovy sales came in at DKK 19.5 billion, but US sales within that figure fell roughly 22% year-over-year, driven by lower prices even as unit volumes rose. International Wegovy sales, by contrast, jumped 46%. Ozempic sales came in at DKK 31.4 billion. Novo had already announced earlier this year that it will cut US list prices roughly 50% for Wegovy and 35% for Ozempic starting January 2027 - a signal that the US pricing pressure now showing up in the numbers is likely to persist.

Why a Guidance Raise Didn't Lift the Stock

This is a clear example of headline direction and stock direction decoupling, and the mechanism is worth breaking down.

• The guidance raise didn't address what investors were actually worried about. The improved outlook came largely from stronger volumes outside the US. The number investors care most about - whether Novo's flagship US obesity and diabetes franchise can hold up against intensifying competition and pricing pressure - actually got worse, not better. A better headline number doesn't move a stock if the underlying detail confirms the market's exact fear.
• The competitive narrative is moving in opposite directions. Rival Eli Lilly has recently posted strong growth in Mounjaro and Zepbound sales alongside repeated guidance raises of its own. Novo's "smaller expected decline" is technically an improvement, but placed next to a competitor reporting outright growth, it reads as relative weakness. Markets price a company's position relative to its peers, not just its own trajectory in isolation.
• This result landed against an already-announced future headwind. With steep 2027 US price cuts already on the calendar, seeing US sales soften today undermines confidence in how the next several quarters will look. Investors price in not just the current quarter, but how long a known negative catalyst is likely to keep weighing on results.

What to Take Away From This

• Don't trade off a single headline metric. Buying purely because a company "raised guidance" would have lost money here. Always check which line items drove the improvement and whether it actually addresses the market's real concern, not just whether the top-line number went up.
• Relative performance within a sector moves stocks. Novo's results only make sense in context next to Eli Lilly's. When evaluating any stock in a competitive sector, always check how its numbers compare to its closest rival's - not just against its own guidance.
• A known future risk gets priced in gradually, not all at once. Pre-announced events like Novo's 2027 price cuts weigh on sentiment every quarter leading up to them, not just on the day they take effect. If a stock you hold has a known headwind on the calendar, expect it to resurface at every earnings report until it's resolved.

For related context, see: AMD Beat Earnings But Fell 8% After Hours - So Why Did Palantir Jump 29%?, SpaceX's First Earnings Report Beats Estimates, Stock Falls 7-8%

Sources

This article synthesizes and analyzes the reporting below in our own words - it is not a reproduction of the original text. For the latest figures and full detail, please refer to the original sources.

• Novo Nordisk stock falls after raised forecast fails to change the debate over its obesity business - CNBC
• Novo Nordisk shares slide after guidance disappoints investors - CNBC
• Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks - Benzinga

⚠️ This article is for informational purposes only and is not investment advice. Market conditions change constantly - always verify the latest data yourself before making any investment decision.